BACKGROUND: Decreased activity of serum desoxyribonuclease I (DNase I) in systemic lupus erythematosus (SLE) has been reported, but its role as a biomarker in SLE is still unelucidated. METHODS: Seventy-seven SLE patients (aged 39.6 ± 13.1 years) were studied for serum DNase I activity, levels of antinuclear (ANA), anti-dsDNA [high-avidity ELISA, conventional ELISA and indirect immunofluorescence (IIF)], anti-nucleosome, anti-histone antibodies, complement components C3 and C4. SLE disease activity was evaluated by disease activity index (SLEDAI-2K). Thirty-five patients were serologically and clinically followed for 3-12 months (mean 5.6 ± 2.8). Thirty-seven healthy blood donors were the control group. RESULTS: DNase I activity in SLE patients was lower than in healthy controls (p<0.01). DNase I activity was in positive correlation with SLEDAI-2K (p<0.01), levels of ANA, anti-dsDNA, anti-nucleosome and anti-histone antibodies (p<0.01) and in negative correlation with C3 concentration (p<0.05). The highest correlation was found between DNase I activity and anti-dsDNA concentrations determined by high-avidity ELISA (r=0.624), followed by IIF (r=0.541) and conventional ELISA (r=0.405). In the follow-up study, DNase I activity also correlated with SLEDAI-2K (p<0.01). SLE patients with low DNase I activity more frequently had SLE-specific cutaneous lesions (p<0.05). CONCLUSIONS: Monitoring of DNase I activity simultaneously with SLEDAI-2K might be a useful tool in the follow-up of SLE. An increase of DNase I activity characterized relapse in most SLE patients, although it did not reach the levels of healthy individuals. A decrease of DNase I activity in SLE flare-ups might be a functional biomarker of a subset of patients with specific dysfunction of apoptotic chromatin degradation.
BACKGROUND: Decreased activity of serum desoxyribonuclease I (DNase I) in systemic lupus erythematosus (SLE) has been reported, but its role as a biomarker in SLE is still unelucidated. METHODS: Seventy-seven SLEpatients (aged 39.6 ± 13.1 years) were studied for serum DNase I activity, levels of antinuclear (ANA), anti-dsDNA [high-avidity ELISA, conventional ELISA and indirect immunofluorescence (IIF)], anti-nucleosome, anti-histone antibodies, complement components C3 and C4. SLE disease activity was evaluated by disease activity index (SLEDAI-2K). Thirty-five patients were serologically and clinically followed for 3-12 months (mean 5.6 ± 2.8). Thirty-seven healthy blood donors were the control group. RESULTS: DNase I activity in SLEpatients was lower than in healthy controls (p<0.01). DNase I activity was in positive correlation with SLEDAI-2K (p<0.01), levels of ANA, anti-dsDNA, anti-nucleosome and anti-histone antibodies (p<0.01) and in negative correlation with C3 concentration (p<0.05). The highest correlation was found between DNase I activity and anti-dsDNA concentrations determined by high-avidity ELISA (r=0.624), followed by IIF (r=0.541) and conventional ELISA (r=0.405). In the follow-up study, DNase I activity also correlated with SLEDAI-2K (p<0.01). SLEpatients with low DNase I activity more frequently had SLE-specific cutaneous lesions (p<0.05). CONCLUSIONS: Monitoring of DNase I activity simultaneously with SLEDAI-2K might be a useful tool in the follow-up of SLE. An increase of DNase I activity characterized relapse in most SLEpatients, although it did not reach the levels of healthy individuals. A decrease of DNase I activity in SLE flare-ups might be a functional biomarker of a subset of patients with specific dysfunction of apoptotic chromatin degradation.
Authors: Sebastian Boeltz; Poorya Amini; Hans-Joachim Anders; Felipe Andrade; Rostyslav Bilyy; Simon Chatfield; Iwona Cichon; Danielle M Clancy; Jyaysi Desai; Tetiana Dumych; Nishant Dwivedi; Rachael Ann Gordon; Jonas Hahn; Andrés Hidalgo; Markus H Hoffmann; Mariana J Kaplan; Jason S Knight; Elzbieta Kolaczkowska; Paul Kubes; Moritz Leppkes; Angelo A Manfredi; Seamus J Martin; Christian Maueröder; Norma Maugeri; Ioannis Mitroulis; Luis E Munoz; Daigo Nakazawa; Indira Neeli; Victor Nizet; Elmar Pieterse; Marko Z Radic; Christiane Reinwald; Konstantinos Ritis; Patrizia Rovere-Querini; Michal Santocki; Christine Schauer; Georg Schett; Mark Jay Shlomchik; Hans-Uwe Simon; Panagiotis Skendros; Darko Stojkov; Peter Vandenabeele; Tom Vanden Berghe; Johan van der Vlag; Ljubomir Vitkov; Maren von Köckritz-Blickwede; Shida Yousefi; Alexander Zarbock; Martin Herrmann Journal: Cell Death Differ Date: 2019-01-08 Impact factor: 15.828
Authors: Andrew J Monteith; SunAh Kang; Eric Scott; Kai Hillman; Zenon Rajfur; Ken Jacobson; M Joseph Costello; Barbara J Vilen Journal: Proc Natl Acad Sci U S A Date: 2016-03-28 Impact factor: 11.205
Authors: Jonatan Leffler; Katarzyna Ciacma; Birgitta Gullstrand; Anders A Bengtsson; Myriam Martin; Anna M Blom Journal: Arthritis Res Ther Date: 2015-08-13 Impact factor: 5.156